Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Vertex (VERX) Beat Estimates Again in Its Next Earnings Report?
Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Vertex Pharmaceuticals (VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes.
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities.
Final Trades: Vertex Pharma, Netflix and the IYF
The Investment Committee give you their stop stocks to watch for the second half.
Vertex: Expectations Reset With Improved Fundamentals (Rating Upgrade)
I upgrade my rating for Vertex stock to buy due to the recent valuation pullback, creating an attractive entry point at 7x forward revenue. VERX's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24 and management projecting 28% y/y growth for FY25. ERP migrations from SAP and Oracle provide a multiyear pipeline, with a $1.8 billion TAM through 2028, supporting ARR growth.
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point
Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.
Goldman Sachs Analyst Anticipates Clarity On Vertex's Investment Roadmap And Product Monetization At Investor Day
Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. VERX ahead of its first Investor Day as a public company on March 19.
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
